Qiao Gui-bin, Zeng Wei-sheng, Peng Li-jun, Jiang Ren-chao, Pang Da-zhi, Peng Xiu-fan, Wu Yi-long
Department of Thoracic Surgery, Guangzhou General Hospital of Guangzhou Military Command, Guangdong Lung Cancer Research Institute, Guangzhou 510010, China.
Zhonghua Wai Ke Za Zhi. 2009 Jul 15;47(14):1052-4.
The staging and treatment of multi-focal non-small cell lung cancer (NSCLC) are controversial. This study evaluated the effectiveness of surgical treatment for the ipsilateral multi-focal NSCLC.
Sixty-eight patients with multi-focal NSCLC underwent complete resection from December 1999 to December 2006. This series included 44 males and 24 females, with a mean age of 60.3 years old (range from 33 to 81 years old). Fifty-four patients had multiple nodules in primary lobe (T4) and 13 patients had additional nodules in non-primary lobe (M1), and a patient was proved to have synchronous primary NSCLC lesions. Surgical treatments included lobectomy in 53 cases, bilobectomy in 4 cases, pneumonectomy in 2 cases, and lobectomy combined with wedge resection in 9 cases.
The median overall survival time of this series was 30 months. Prognostic study demonstrated that mediastinal lymph node metastasis and bronchioloalveolar carcinoma histology had significant impact on overall survival. The median survival times were 39 months for patients with N0 and N1, and 14 months for patients with N2, respectively, and there was significant difference between the groups (P < 0.01). The difference in survival was significant between patients with bronchioloalveolar carcinoma components and other NSCLC histologic types (P < 0.01), and the median survival times were 46 months and 20 months, respectively.
Surgery could provide choice for multi-focal NSCLC patients (T4 and M1), especially for patients with bronchioloalveolar carcinoma components and without mediastinal lymph node metastasis.
多灶性非小细胞肺癌(NSCLC)的分期及治疗存在争议。本研究评估了同侧多灶性NSCLC手术治疗的有效性。
1999年12月至2006年12月,68例多灶性NSCLC患者接受了根治性切除。该组包括44例男性和24例女性,平均年龄60.3岁(范围33至81岁)。54例患者在主叶有多个结节(T4),13例患者在非主叶有额外结节(M1),1例患者被证实有同步原发性NSCLC病灶。手术治疗包括肺叶切除术53例、双肺叶切除术4例、全肺切除术2例、肺叶切除术联合楔形切除术9例。
该组患者的中位总生存时间为30个月。预后研究表明,纵隔淋巴结转移和细支气管肺泡癌组织学对总生存有显著影响。N0和N1患者的中位生存时间分别为39个月和14个月,两组间差异有统计学意义(P<0.01)。有细支气管肺泡癌成分的患者与其他NSCLC组织学类型患者的生存差异有统计学意义(P<0.01),中位生存时间分别为46个月和20个月。
手术可为多灶性NSCLC患者(T4和M1)提供选择,尤其是对于有细支气管肺泡癌成分且无纵隔淋巴结转移的患者。